Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PPSGG (PN-1007) in Anti-MAG Neuropathy Patients

NCT04568174 is registered in ClinicalTrials.gov with Polyneuron Pharmaceuticals AG as lead sponsor.

NCT NCT04568174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04568174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PPSGG (PN-1007) in Anti-MAG Neuropathy Patients
Lead sponsor
Polyneuron Pharmaceuticals AG
Phase
Phase 1/2
Overall status
Terminated
Start date
November 17, 2020
Completion date
September 23, 2021
Enrollment
1 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

anti-mag neuropathy